Evolution of high dose stem cell therapy in multiple myeloma

Ajay Gupta, Lalit Kumar

Max Cancer Center, Saket, 'Dr. BRA IRCH, AIIMS, New Delhi, India

Address for correspondence:
Dr. Ajay Gupta,
P-41, South Extension-2,
New Delhi, India.
E-mail: ajayajaygupta2002@rediffmail.com

ABSTRACT

Conventional chemotherapy has been used in the treatment of multiple myeloma. However, the development of autologous stem cell transplant represented a major advance in its therapy. Complete response (CR) rates to the tune of 40-45% were seen and this translated into improvements in progression-free survival and also overall survival in some studies. As a result, the autologous stem cell transplants (ASCT) is the standard of care in eligible patients and can be carried out with low treatment-related mortality. Allogenic transplant carries the potential for cure but the high mortality associated with the myeloablative transplant has made it unpopular. Reduced intensity stem cell transplants (RIST) have been tried with varying success but with a high degree of morbidity as compared to the ASCT. Introduction of newer agents like thalidomide, lenalidomide, bortezomib and liposomal doxorubicin into the induction regimens has resulted in higher CR and very good partial response rates (VGPR) as well as improvement in ease of administration. These drugs have also proved useful in patients with adverse cytogenetics. Recent trials suggest that this has translated into improvements in response rates post-ASCT. There is a suggestion that patients achieving CR/nCR or VGPR after induction therapy should be placed on maintenance and ASCT then could be used as a treatment strategy at relapse. All these trends however await confirmation from further trials. Tandem transplants have been used to augment the results obtained with ASCT and have demonstrated their utility in patients who achieved only a partial response or stable disease in response to the first transplant as well as patients with adverse cytogenetics. Incorporation of bortezomib along with melphalan into the conditioning regimen has also been tried. RIST following ASCT has been tried with varying success but does not offer any major advantage over ASCT and is associated with higher morbidity. It is hoped that recent advances in therapy will contribute greatly to improved survival.

Key words: Conventional chemotherapy, high dose stem cell therapy, multiple myeloma

INTRODUCTION

Multiple myeloma is a malignant disorder characterized by proliferation of plasma cells. It accounts for 10% of hematological cancers and 1% of all cancers. The disease is uniformly fatal with a median survival of approximately 3 years with conventional chemotherapy (CC) although the outlook has improved with the integration of newer therapies including high dose therapy (HDT) followed by autologous stem cell transplants (ASCT).

Multiple myeloma is currently the most common indication for ASCT in North America and Europe. ASCT remains the standard of care in eligible patients aged below 65-70 years (though age is not a criterion in the United States) performed either upfront or at relapse. It is mostly performed upfront after induction therapy. The attainment of complete response (CR) is held to be a surrogate for improved survival and is the aim of the ASCT.

CR is characterized by undetectable serum and urine monoclonal proteins (by immnofixation), absence of plasmacytosis (<5% plasma cells in marrow), disappearance of plasmacytomas and stable or improving bone disease. Stringent CR (sCR) is a new criterion which refers to normalization of the free light chain ratios (FLC) as well as the absence of monoclonal plasma cells in the marrow. Very good partial response (VGPR) refers to the absence of monoclonal proteins by electrophoresis but not by
immunofixation or more than 90% reduction in level of serum M component proteins as well as urinary M proteins less than 100 mg/24 hours.[1]

With conventional chemotherapy comprising melphalan and prednisolone, CR was attained in less than 5% patients. However the median OS in patients achieving CR was 5.1 years as compared to 3.3 years for other responders.[1] ASCT has helped improve CR and VGPR rates over and above CC and is usually performed after induction therapy as consolidation.

Lately the introduction of newer agents like bortezomib, lenalidomide, thalidomide, liposomal doxorubicin and the like has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher rates of CR and very good partial response (VGPR) seen with these agents has led to their integration into induction therapies. It has raised issues regarding redefining the inclusion criteria/timing and expected benefits of ASCT over and above maintenance with these therapies especially in responding patients. This however awaits further trials.

**ASCT IN MULTIPLE MYELOMA**

Prospective randomized trials have been conducted to evaluate the efficacy of ASCT in terms of attainment of CR, response rate (RR), improvements in progression free survival (PFS) and overall survival (OS) as well as transplant-related mortality (TRM).[3-8]

CR rates, median PFS, median OS and TRM have ranged from 17 to 44.5%, 25 to 42 months, 47.8 to 67 months and 3 to 7%, respectively.[3-8]

However, only two of the trials, the French Intergroup Study (IFM)[3] and the British (MRC VII trial),[4] demonstrated a survival advantage with ASCT. The French trial demonstrated median OS of 57 months vs. 37 months and the British trial demonstrated a median OS of 54.1 months vs. 42.3 months of ASCT over conventional chemotherapy (CC).

However other trials had some deficiencies. The Spanish study (PETHEMA) demonstrated improved CR rates (30% vs. 11%) with ASCT as compared to CC but no improvement in OS (61 vs. 66 months). This has been ascribed to the fact that only responding patients were taken up for transplant. Refractory patients who were not taken up for the study could also have derived benefit from ASCT.[5]

Two of the trials were designed specifically to look at the effect of upfront vs. delayed (in the case of relapse or refractory disease) upon the survival rates. There was no difference in OS though the French trial reported higher CR rates and better PFS in favor of early transplant.[6,7]

In another large US intergroup trial comparing CC with ASCT no difference could be demonstrated partly because of the cross over allowed for transplant at relapse in patients on the CC arm as also the fact that the combination of total body irradiation and melphalan dose of 140 mg/m$^2$ rather than the standard 200 mg/m$^2$ resulted in a disappointing CR rate of 17%.[8]

The trials incorporating melphalan and TBI had lower CR rates (17-22%) as compared to those in which melphalan 200 mg/m$^2$ was used resulting in CR rates of 30-44%.[14,17] Thus melphalan 200 mg/m$^2$ is now the conditioning regimen of choice. These days, most centers claim a TRM of 1% or less, thus rendering ASCT an acceptably safe treatment modality.

CR has been demonstrated to be the most important factor influencing long term survival. In the French IFM study, patients achieving a CR/VGPR had significantly higher 5 year OS rates of 72% as compared to 39% among patients who had a PR.[8] In a retrospective analysis of 721 newly diagnosed patients who underwent ASCT it was found that patients achieving CR had a median survival of 9-14 years compared to 5.9 years for patients who achieved PR.[9]

**IMPROVING EFFICACY OF ASCT**

**Induction therapy and the effect of ASCT**

The most common treatment strategy involves use of induction chemotherapy followed by HDT- ASCT (in eligible patients).

**Initial regimens (vincristine, adriamycin, dexamethasone/ dexamethasone/thalidomide, dexamethasone)**

Initially the most popular regimens used were single agent pulsed dexamethasone or vincristine, adriamycin and dexamethasone (VAD). Response rates (RR) of 40-43% (CR rates ranging from 0 to 3%) have been reported with dexamethasone.[10,12] With VAD RR ranging from 52 to 67% and CR rates ranging from 3 to 9% have been described.[13,14]

Following VAD the next common induction regimen was the oral regimen of thalidomide and dexamethasone (TD); RR ranging from 76 to 80% and CR rates ranging from 7 to 25% have been observed.[12,15]

After ASCT, CR rates ranging from 30 to 48.2% (post VAD induction) have been described.[13,14,16] However studies using thalidomide/dexamethasone and single agent
dexamethasone have demonstrated essentially similar results.[10-16]

In a study it was found that at 6 months post-transplant, the benefit of ThalDex over VAD was not seen and the VGPR or better rates were comparable (44.4% in the ThalDex arm and 41.7% in the VAD arm).[14] Thus ASCT seems to cover for the seeming inefficiencies of these induction regimens.

**NEWER COMBINATIONS: PROMISE AND PREMISE**

**Bortezomib and dexamethasone**

The doublet of bortezomib and dexamethasone (VD) has been associated with RR ranging from 67 to 88% (VGPR or better rates ranging from 23 to 47%) and CR/nCR rates ranging from 13 to 21%. Post-ASCT, RR in the range of 90%, CR/nCR rates of up to 35% and VGPR or better rates up to 62% have been described.[17-20]

**Lenalidomide and dexamethasone**

Lenalidomide and dexamethasone (LD) use was associated with RR of 91% and 18% CR rates. In patients who underwent ASCT the 2 year OS and PFS was 92% and 83% respectively as compared to 90% and 59% for those who did not undergo ASCT. However the yield of stem cells diminished upon prolonged use of this combination and hence it has been suggested that an early stem cell harvest might be necessary in the case of patients planned for delayed ASCT.[21]

**Bortezomib-based combinations with other drugs**

Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction using bortezomib 1.3 mg/m² (PAD1, N=21) or 1.0 mg/m² (PAD2, N=20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% post-induction and 81%/53% post-transplant. PFS (29 vs. 24 months), OS (2 years: 95% vs. 73%) were statistically similar but favored PAD1 versus PAD2.[22] Thus standard dose bortezomib was associated with better response rates as compared to the lower dose in which however the toxicity was lesser. This result was also suggested in earlier reports. With low dose bortezomib, CR rates of 11% were seen which improved to 37% post-ASCT.[23] RR of 95% and CR rates of 24% was seen with standard dose bortezomib and post-ASCT CR rates improved to 57% (81% had VGPR or better responses).[24]

**Liposomal doxorubicin-based regimens**

Bortezomib, liposomal doxorubicin and dexamethasone have been used with RR 93% (63% VGPR or better) and CR rates of 43%. Following ASCT CR rates improved to 65% (75% of the responses were VGPR or better).[25] In regimens excluding dexamethasone (Bortezomib, Liposomal Doxorubicin alone) RR of 79% and CR rates of 28% have been observed.[20]

The three drug regimen of dexamethasone, vincristine, liposomal doxorubicin (DVd) yielded response rates of 66%.[27] 4 drug regimens comprising of dexamethasone, vincristine, liposomal doxorubicin and thalidomide (DVd+T) have been used with RR 74-83% and CR rates varying from 10-36%.[28-29]

**Bortezomib and thalidomide/ lenalidomide combinations**

The three drug combination (VTD) of bortezomib, thalidomide and dexamethasone has resulted in 87% RR and up to 36% CR/nCR rates. After ASCT, CR/nCR rates improved to 57%. VGPR or better rates were seen in 77% cases. In this GIMEMA trial the high CR rates achieved after induction with VTD were not influenced by the presence of deletion 13 or t(4;14) thus suggesting their role in overcoming high risk cytogenetics.[34]

Use of VDT PACE (cisplatin, doxorubicin, dexamethasone, etoposide) resulted in OR 89% and CR rates of 22%. After ASCT CR/nCR rates improved to 75%.[31]

The combination of lenalidomide, bortezomib, dexamethasone yielded CR rates of 20% and RR of 87%.[32] Thus ASCT improves upon the response rates of the induction regimens including those incorporating newer agents.

**Tandem transplants**

Tandem transplants have been used to improve the results of ASCT. 69% CR rates were reported with tandem ASCT in a very select group of patients.[33] Barlogie reported a 41% CR rate with such a strategy (total therapy).[34] Attal et al compared single vs. tandem ASCT in 399 patients and found that though the CR rates were equivalent (42 vs. 50%), the 7 year EFS and OS were significantly improved (10% vs. 20% EFS, 21% vs. 42% OS),[35] while the Bolognial[36] trial has not shown a significant benefit for tandem transplantation.

Tandem transplants are useful in patients having PR or stable disease in response to the first transplant and are not usually recommended in those who have had a CR or VGPR.

Additionally it has been suggested that the negative impact of having both cytogenetic abnormalities: deletion 13 and t(4;14), which were associated with very low VGPR rates with TD, were offset by tandem transplantation. The VGPR rates were 12% in this subgroup of patients as compared to VGPR rates of 41-50% in patients with either
of these abnormalities when given an induction regimen comprising of TD. The 3 year PFS and OS were nearly identical after tandem ASCT (70% vs. 77% and 92% vs. 88%, respectively).[37]

**Newer agents in tandem ASCT**

The total therapy II trial included thalidomide into the induction, consolidation, tandem ASCT and maintenance strategy. After transplantation the CR rate in the thalidomide arm was 62% vs. no thalidomide 43% and though the EFS improved (48% vs. 38%) there was no difference in OS because of the more aggressive nature of the disease at relapse in those who were on thalidomide.[38,39]

The total therapy III trial has incorporated VDT-PACE into induction, consolidation, tandem ASCT and maintenance strategy and have reported 83% CR/nCR rates for patients 24 months into the program.[40]

With better CR/VGPR rates after a single ASCT seen upon incorporation of the newer induction regimens, the requirement of a tandem transplant is expected to reduce.

**Use of drug combinations: Bortezomib and melphalan in the conditioning regimen**

In a preliminary study, a combination of bortezomib and melphalan was used in the conditioning regimen in 35 poor risk patients (including those who did not achieve VGPR after a first transplant). Three months after ASCT, 63% VGPR including 31% CR was observed suggesting that the combination had the potential to better the responses seen with melphalan alone but this would require confirmation from other studies: especially from those in which bortezomib was used as the induction regimen.[41]

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE SETTING OF RENAL FAILURE**

The Arkansas group studied autologous SCT in 81 patients with renal failure (including 38 patients on dialysis). Melphalan 140 mg/m² appeared as effective as melphalan 200 mg/m² as a conditioning regimen and was less toxic. 13 (24%) of the 54 patients evaluable for renal function improvement became dialysis free at a median of 4 months after transplant. 5 year EFS and OS of 59 patients on dialysis at the time of ASCT were 24% and 36%,[42,43]

The PETHEMA (Spanish) group reported studied 14 patients and reported a TRM of 29% and a 3 year OS of 49%.[44]

In another study involving 46 patients with myeloma and renal impairment (21% dialysis dependent), 15(32%) showed improvement of CrCl of at least 25% above baseline. TRM of 4% and 3 year PFS and OS of 36% and 64% were reported.[45]

**ALLOGENIC STEM CELL TRANSPLANTATION**

Allogenic SCT has the potential to induce molecular remissions and is at least theoretically the only possible curative treatment modality.[46,47] The high incidence of infections and GVHD has limited its utility.

Initial studies suggested a CR rate of 44%. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of patients in CR after BMT was 34% at 6 years.[48]

Most studies have reported TRM’s ranging from 37-55% while only the EBMT study (1994-1998) reported a TRM of 30%.[49] Data suggest that only 10-20% patients are long term survivors:

Many of them in molecular remission.[49-52]

Neither use of peripheral blood stem cells or T cell depletion has resulted in a decrease in TRM.[53,54]

In the Dutch-Belgian Hemato-Oncology Cooperative Group, T cell-depleted allogeneic transplantation in 53 patients resulted in a medial survival of only 25 months.[55]

A similar treatment strategy employed at Dana Farber in 66 patients resulted in a nonrelapse TRM of 35%, with a PFS at 4 years of 23%.[47]

The toxicities of the procedure limit it’s use to the minority of patients who are less than 55 years of age and have a HLA matched donor. Even then, the high TRM results in short term survival benefits in favor of the autologous transplant as compared to the allogenic transplant thus making this treatment strategy unviable at most centers.[56]

**REDUCED INTENSITY ALLOGENIC TRANSPLANTATION**

This treatment strategy was implemented in order to reduce the TRM while retaining the graft versus myeloma effect.[57-63]

The conditioning regimens consisted of 1) Fludarabine /melphalan with / without in vivo T cell depletion with antithymocyte globulin (ATG) or alemtuzumab or 2) low dose TBI with/without fludarabine.[57-63]
This strategy has also been associated with substantial toxicity with a TRM of approximately 20%, acute GVHD rates of 30% and chronic GVHD rates of 50%. Low tumor burden at time of transplantation was associated with better survival.[57-63]

TANDEM AUTOLOGOUS AND REDUCED INTENSITY ALLOGENIC TRANSPANTATION

The strategy of reducing tumor load with autologous transplant and following up with reduced intensity allogeneic transplantation has also been studied. In one major study, TRM at 100 days was 11%, the incidence of acute and chronic GVHD were 38% and 40% respectively: the CR rate being 73%.[64]

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin has been studied and found to be effective with relatively low transplantation-related mortality: I year TRM of 26% and CR rate of 40%.[65]

RIST using TBI of 2 Gy as the conditioning regimen were associated with CR rates of 53-57%, chronic GVHD rates of 74% and an EFS of 36-37% with a PFS of 25-30% 6 years post transplant.[66-67]

REDUCED INTENSITY CONDITIONING REGIMENS

3 studies have compared tandem ASCT with tandem ASCT/ RIST. Tandem ASCT/RIST arms were associated with TRM ranging from 11-18%, 50% to 74% incidence of extensive chronic GVHD, one-third of the patients were on immunosuppressive drugs at 5 years, donor lymphocyte infusions were ineffective at relapse, and PFS and OS was similar to tandem ASCT except in the Italian study which found an increased CR rate and survival advantage with allogeneic ASCT.[68-70] In view of these differing studies, the results of a major ongoing Bone Marrow Transplant Clinical Trial Network study are eagerly awaited.

In our opinion RIST should not be offered outside of a clinical trial in view of significant TRM and GVHD risks as compared to autologous SCT.

DISCUSSION

ASCT represents one of the most important therapeutic options in the treatment of eligible patients suffering from multiple myeloma.

Newer drugs like thalidomide, bortezomib and lenalidomide have been used. Studies have demonstrated that ASCTs performed after induction incorporating these new agents is associated with higher response rates. The OS benefit seen with these treatment strategies shall become evident in course of time once the final results of these trials become known.

These drugs have also been combined with chemotherapeutic agents and used in patients ineligible for transplants. Regimens like MPT (melphalan, prednisone and thalidomide),[71-73] MPV (melphalan, bortezomib and prednisone)[74] and MPR (melphalan, prednisone and lenalidomide)[75] have yielded impressive results with RR varying from 76% to 89% and CR rates varying from 15.6 to 30%. The MPT regimen was in fact superior to the intermediate dose (melphalan 100 mg/m²) ASCT.[73] However the survival benefit has to be assessed against high dose chemotherapy as against intermediate dose (melphalan 100 mg/m²) ASCT in order to claim whether these treatments are equivalent or superior to HDT-ASCT.

There is a debate whether patients in CR/nCR or even VGPR after induction therapy should be subjected to upfront ASCT or placed on maintenance therapy. In such a situation ASCT could then serve as a treatment option at relapse.

The role of allogeneic transplantation also keeps evolving but is tempered by the spectre of increased procedure-related morbidity and mortality.

As of now, ASCT remains the standard of care in eligible patients. Better induction strategies will hopefully improve the results of the ASCT in terms of prolonged overall and progression-free survival in patients suffering from multiple myeloma. Myeloablative allogeneic transplant has gone out of favour. Non myeloablative transplants done after initial ASCT offer some promise but at the expense of great morbidity and at present cannot be offered outside the purview of a clinical trial.

REFERENCES

1. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol 1998;16:3832-42.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
5. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHHEMA. Blood 2005;106:3755-9.

6. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998;92:3131-6.

7. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33.

8. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemo radiation therapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36.

9. Wang M, Delasalle K, Thomas S. Complete remission represents the major surrogate marker of long term survival in multiple myeloma. Blood 2006;108:123a-4a.

10. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary thalidomide treatment of multiple myeloma. Blood 1992;80:887-90.

11. Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-8.

12. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.

13. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and Dexamethasone over Vincristine-Doxorubicine-Dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.

14. Macro M, Divine M, Uzunban Y. Dexamethasone + Thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: A randomized trial. Blood Vol. 108. 2006.

15. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-7.

16. Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant 2008;41:1013-9.

17. Harousseau JL, Attal M, Leleu X, Troncy J, Pégourie B, Stoppa AM, et al. Bortezomib plus dexamethasome as induction treatment prior to autologous transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 2006;91:1498-505.

18. Jagnnath S, Durie BG, Wolf JL. Long term follow up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood 2006;108:238a-9a.

19. Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, et al. Phase II PETHHEMA trial of alternating bortezomib and dexamethasone as induction regime before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452-8.

20. Harousseau JL, Marit G, Calliot D. VELCADE / dexamethasone(Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 2006;108:21a.

21. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM; Katab B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma. Blood 2005;105:4050-3.

22. Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br J Haematol 2008;141:512-6.

23. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2008;129:755-62.

24. Popat R, Oakervee HE, Curry N. Reduced dose PAD combination therapy (PS-341/Bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005;106:717a.

25. Jakobowiak AJ, Al-Zoubi A, Kendall T. Combination therapy with bortezomib (VELCADE), Doxil, and dexamethasene (VDD) in newly diagnosed myeloma: Updated results of phase II clinical trial. Haematologica 2007;92:PO-721.

26. Orlowski RZ, Peterson BL, Sanford B. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma. Br J Haematol 2005;129:755-62.

27. Zervas K, Mihou D, Katodritou I. VAD - doxil versus VAD doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of the Greek Myeloma Study Group. Blood 2006;108:238a.

28. Hussein MA, Baz R, Skalovíc G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasene, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95.

29. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncol 2004;5:134-8.

30. Cavo M, Patria F, Tacchetti P, Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma. Blood 2007;110:30a.

31. Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma 2006;7:210-6.

32. Richardson PG, Jagannath S, Raje NS. Phase 1/2 study of upfront Rev/Vel/Dex in MM. Early results. Hematologica 2007;92:PO-715.

33. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myélome. Semin Hematol 2001;38:226-30.

34. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.

35. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med
Thalidomide and hematopoietic stem-cell transplantation for multiple myeloma: a prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;10:2434-41.

Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-40.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, Van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.

Shaughnessy JD, Haessler J, Zeldis J. An update on the role of thalidomide (THAL) in Total Therapy 2 (TT2) for newly diagnosed patients with multiple myeloma (MM): Analysis of subgroups defined by standard prognostic factors (SPF) and gene expression profiling (GEP) – derived subgroups. Blood 2006;108:968a.

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating zebularine into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007;138:176-85.

Attl M, Moreau P, Aver-Loiseau H, Harousseau JL. Stem cell transplantation in multiple myeloma. Hematology Am Soc Hematol Educ Program 2007. p. 311-6.

Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplantation in multiple myeloma patients with renal failure. Br J Haematol 2003;114:822-9.

Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis dependent renal failure in patients with myeloma can be reversed by high-dose myeloblastic therapy and autotransplant. Bone Marrow Transplant 2004;33:823-8.

San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28-36.

Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti I, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:812-6.

Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.

Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-host disease. Blood 2003;102:1145-51.

Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-22.

Gahrton G, Svensson H, Cavo M, Bacigalupo A, Björkstrand B, Bladé J, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-16.

Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94.

Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 2003;21:4950-2.
nonmyeloablative allografting. Blood 2009;113:3383-91.

67. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375-82.

68. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high risk de novo multiple myeloma. Blood 2006;107:3474-80.

69. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autograft for newly diagnosed myeloma. N Engl J Med 2007;356:1110-20.

70. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-93.

71. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825-31.

72. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 2008;112:3107-14.

73. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370:1209-18.

74. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.

75. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65.

How to cite this article: Gupta A, Kumar L. Evolving role of high dose stem cell therapy in multiple myeloma. Indian J Med Paediatr Oncol 2011;32:17-24.

Source of Support: Nil, Conflict of Interest: None declared.